InVivoSIM anti-human EGFR (Cetuximab Biosimilar)

Gupta S, Pal R, Schmidt EJ, et al. Miniaturized Fab' imaging probe derived from a clinical antibody: Characterization and imaging in CRISPRi-attenuated mammary tumor models. iScience. 2024,27(8):110102. doi: 10.1016/j.isci.2024.110102

Iadonato S, Ovechkina Y, Lustig K, et al. A highly potent anti-VISTA antibody KVA12123 - a new immune checkpoint inhibitor and a promising therapy against poorly immunogenic tumors. Front Immunol. 2023,14:1311658. doi: 10.3389/fimmu.2023.1311658

Lee DH, Ahn H, Sim HI, et al. A CRISPR activation screen identifies MUC-21 as critical for resistance to NK and T cell-mediated cytotoxicity. J Exp Clin Cancer Res. 2023,42(1):272. doi: 10.1186/s13046-023-02840-9

Müller T, Tasser C, Tesar M, et al. Selection of bispecific antibodies with optimal developability using FcRn‑Ph‑HPLC as an optimized FcRn affinity chromatography method. MAbs. 2023,15(1):2245519. doi: 10.1080/19420862.2023.2245519

Linde IL, Prestwood TR, Qiu J, et al. Neutrophil-activating therapy for the treatment of cancer. Cancer Cell. 2023,41(2):356-372.e10. doi: 10.1016/j.ccell.2023.01.002